Epidemiology The incubation period of hepatitis A is 15–50 days, with a mean of about 30
days. HAV is excreted in the faeces for 1–2 weeks before the onset of illness, and for at least …

Over the last few decades, different types of inactivated hepatitis A virus (HAV) vaccines
have been developed: several aluminum-adjuvanted vaccines and an aluminum-free …

At least five different viruses cause hepatitis in humans. Two—hepatitis A virus (HAV) and
hepatitis E virus (HEV)—are nonenveloped RNA viruses that are spread predominantly by …

There is a need for more efficacious inactivated influenza vaccines, since current
formulations show suboptimal immunogenicity in at-risk populations, like the elderly. More …

Hepatitis A is one of the most common vaccine-preventable infectious diseases in the world.
Effective vaccines against hepatitis A have been available since 1992, and they provide …

Introduction: Liposomes are well-known as drug carriers, and are now critical components of
two of six types of adjuvants present in licensed vaccines. The liposomal vaccine adjuvant …

Numerous vehicles exist to present antigens to the immune system (Table 1). This review
focuses on two types of promising lipid particulate systems: liposomes and ISCOMs. The …

In this study we investigated a new liposomal hepatitis A vaccine (Epaxal®) developed by
the Swiss Serum and Vaccine Institute clinically and immunologically using a one dose …

Publisher Summary This chapter provides an overview of Hepatitis A, one of the oldest
diseases known to humankind. Hepatitis A is a self-limited disease that results in fulminant …

Current SARS-CoV-2 vaccines are effective, but long-term protection is threatened by the
emergence of virus variants. We generated a virosome vaccine containing the Beta spike …